EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis

NACompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

April 2, 2024

Study Completion Date

May 14, 2024

Conditions
Multiple Sclerosis
Interventions
DEVICE

EXOPULSE MOLLII SUIT (active)

"This study aims to evaluate the effects of the EXOPULSE Mollii suit, a non-invasive assistive device that delivers transcutaneous electrostimulation. The suit includes a CE-labeled class IIa control unit and class I body garments. Equipped with 58 electrodes, the full-body suit stimulates various muscle groups to reduce spasticity by activating antagonistic muscles through reciprocal inhibition, rather than causing muscle contractions. Designed to relax spastic muscles, improve range of motion, prevent atrophy, enhance circulation, and provide pain relief, the device is easy to use, requiring only one hour of daily wear, with effects lasting over 24 hours.~Current treatments for spasticity, such as botulinum toxin and oral medications, have limitations like side effects and minimal mobility improvement. The EXOPULSE Mollii suit offers an innovative alternative, with early studies indicating positive impacts on mobility and motor function."

DEVICE

EXOPULSE MOLLII SUIT (sham)

In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.

Trial Locations (1)

94000

Clinical Neurophysiology Department, Henri Mondor Hospital, Créteil

All Listed Sponsors
lead

Institut De La Colonne Vertebrale Et Des Neurosciences

OTHER